Access the Investor Brief
A typical pharmaceutical company has limited, if any, patient data supporting their drug candidates before FDA trials.
Our team has collectively developed 43 FDA-approved drugs worth billions in revenue and treated tens of millions of patients.
We’ve leveraged Dr. Shackelford’s database to find our first drug opportunity. This treatment could help 1.3 million people with epilepsy who haven’t found a treatment that works. This is a $3-billion market alone. Next we will use our database to develop a dozen more potential drug candidates we have identified. It’s only the beginning, as Dr. Shackelford says.
Grew 180% between Phase 2 stage and full FDA approval
Jumped 847% between Phase 2 and Phase 3 completion
Popped 300% higher between Phase 2 and full FDA approval
The median valuation for central nervous system companies with a drug in Phase 2 trials is 437% higher than ours